It has been reported that Cipla reached a settlement with Amgen Inc of the US on pending litigation involving generic cinacalcet hydrochloride tablets. This is used to treat secondary hyperparathyroidism in adult patients with chronic kidney disease. The civil action was filed by Cipla in the US District Court of Delaware and has now been resolved amicably.

Both, Cipla and Amgen have already filed a formal stipulation of dismissal of the case with the court and await signature by the presiding Judge. This resolution will entitle Cipla to continue importing, marketing, and selling Cinacalcet hydrochloride tablets in the US. This is expected to be a positive for the stock price performance of Cipla going ahead.